Upcoming events

Reagan Jarvis, our CEO, is presenting Anocca - 'Showcasing Individualised Neoantigen Discovery Platform' - and will be talking about understanding HLA-restricted neoantigen target complexity with cell-based assays, validating neoantigen targets with T-cell Receptor reagents derived by rapid multiplex discovery and considering TCR potency and safety trade-off for HLA-restricted neoantigens.

Reach out to us if you would like to meet.

Our CTO Luke Pase is at Allogeneic Cell Therapies Summit in Boston  leading the pre-conference workshop “Innovating the Future of Cell Therapy with Next Generation Gene Editing” placing a spotlight on what has been deemed the ‘future of cell therapy’

Reach out to us if you would like to meet.

Hugh Salter, our CSO is at the largest global forum connecting cell and gene therapy translation professionals whicho addresses key topics spanning translational research and preclinical development through to clinical trials, regulatory approvals, commercialization and ultimately patient access.

Reach out to us if you would like to meet.